Abstract
No public abstract is available from the verified source records.
Omar El-Taji, Peter Dutey-Magni, Mick Brown, Macey Murray, Claire Amos, Duncan Gilbert, Max Parmar, Louise Brown, Matthew Sydes, Gert Attard, Nicholas James, Noel W. Clarke, Ashwin Sachdeva
Abstract
Authors
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Chemohormonal therapy in metastatic hormone-sensitive prostate cancer
10.1056/nejmoa1503747 · 2015
Addition of docetaxel, Zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial
10.1016/s0140-6736(15)01037-5 · 2016
Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer
10.1056/nejmoa1704174 · 2017
Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial
10.1016/s0140-6736(18)32486-3 · 2018
Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol
10.1016/s0140-6736(21)02437-5 · 2022
Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol
10.1016/s1470-2045(23)00148-1 · 2023
Enzalutamide with standard first-line therapy in metastatic prostate cancer
10.1056/nejmoa1903835 · 2019
Arches: a randomized, phase 3 study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
unpaywall
Confidence 95%
datacite
Confidence 0%
10.1200/jco.19.00799 · 2019
Apalutamide for metastatic, castration-sensitive prostate cancer
10.1056/nejmoa1903307 · 2019
Darolutamide and survival in metastatic, hormone-sensitive prostate cancer
10.1056/nejmoa2119115 · 2022
Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design
10.1016/s0140-6736(22)00367-1 · 2022
Cardiovascular events and androgen receptor signaling inhibitors in advanced prostate cancer: a systematic review and meta-analysis
10.1001/jamaoncol.2024.1549 · 2024
Improving research for prostate cancer survivorship: a statement from the Survivorship Research in Prostate Cancer (SuRECaP) working group
10.1016/j.urolonc.2019.10.006 · 2020
Major adverse cardiovascular event definitions used in observational analysis of administrative databases: a systematic review
10.1186/s12874-021-01440-5 · 2021
Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85–31
10.1200/jco.2007.12.3752 · 2009
Cardiovascular risk in men with prostate cancer: insights from the RADICAL PC study
10.1097/ju.0000000000000714 · 2020
Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology
10.1161/circulationaha.109.192695 · 2010
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)
10.1093/eurheartj/ehac244 · 2022
Cardiovascular disease risk assessment and multidisciplinary care in prostate cancer treatment with ADT: recommendations from the APMA PCCV expert network
10.1007/s00345-024-04852-2 · 2024
SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europ
10.1093/eurheartj/ehab309 · 2021
10.1093/eurheartj/ehab312
10.1093/eurheartj/ehab312
Data resource profile: hospital episode statistics admitted patient care (HES APC)
10.1093/ije/dyx015 · 2017
Data provenance and integrity of health-care systems data for clinical trials
10.1016/s2589-7500(22)00122-4 · 2022
Fracture-related hospitalisations in newly diagnosed high-risk localised or metastatic hormone-sensitive prostate cancer: secondary analysis of the STAMPEDE phase 3 trials of docetaxel and zoledronic acid using healthcare systems data
10.1016/j.annonc.2025.07.005 · 2025
Validity of acute cardiovascular outcome diagnoses recorded in European electronic health records: a systematic review
10.2147/clep.s265619 · 2020
Completeness and diagnostic validity of recording acute myocardial infarction events in primary care, hospital care, disease registry, and national mortality records: cohort study
10.1136/bmj.f2350 · 2013
Identification of heart failure hospitalization from NHS Digital data: comparison with expert adjudication
10.1002/ehf2.14669 · 2024
Towards better clinical prediction models: seven steps for development and an ABCD for validation
10.1093/eurheartj/ehu207 · 2014
Estimating and comparing time-dependent areas under receiver operating characteristic curves for censored event times with competing risks
10.1002/sim.5958 · 2013
Cardiovascular toxicities of androgen deprivation therapy in Asian men with localized prostate cancer after curative radiotherapy: a registry-based observational study
2022
Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer
10.1200/jco.2006.06.2497 · 2006
Validation of Systematic Coronary Risk Evaluation 2 (SCORE2) and SCORE2-Older Persons in the EPIC-Norfolk prospective population cohort
10.1093/eurjpc/zwad318 · 2024
Patient demographics and major adverse cardiovascular events after androgen deprivation therapy for prostate cancer
10.1155/2024/2988289 · 2024
Cardiovascular mortality in patients with metastatic prostate cancer exposed to androgen deprivation therapy: a population-based study
10.1016/j.clgc.2014.12.003 · 2015
Introduction to the analysis of survival data in the presence of competing risks
10.1161/circulationaha.115.017719 · 2016
Prostate radiotherapy in newly diagnosed metastatic prostate cancer
10.1097/mou.0000000000000675 · 2019
Incidental coronary arterial calcification for cardiovascular risk assessment in men with prostate cancer undergoing PET/CT imaging
10.1016/j.clgc.2024.01.014 · 2024
Evaluating clinical tools to monitor cardiovascular risk in men with prostate cancer receiving hormone therapy
10.1200/op-25-00506 · 2025
Which patients with metastatic hormone-sensitive prostate cancer (mHSPC) benefit more from androgen receptor pathway inhibitors (ARPIs)? STOPCAP meta-analyses of individual participant data (IPD)
10.1200/jco.2025.43.5_suppl.20 · 2025
Unresolved referenced work
Kept as external metadata until matched
Contemporary accuracy of death certificates for coding prostate cancer as a cause of death: is reliance on death certification good enough? A comparison with blinded review by an independent cause of death evaluation committee
10.1038/bjc.2016.162 · doi-reference
Association of patient comorbid conditions with cancer clinical trial participation
10.1001/jamaoncol.2018.5953 · doi-reference
The value of real world evidence and pragmatic trials in advanced prostate cancer- insights from the electronic Prostate Cancer Australian and Asian Database
10.3389/fonc.2024.1494073 · doi-reference
Cardiovascular safety of degarelix versus leuprolide in patients with prostate cancer: the primary results of the PRONOUNCE randomized trial
10.1161/circulationaha.121.056810 · doi-reference